Diana GS Lim on Muck Rack

Diana GS Lim

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Diana GS

Contact Diana GS, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

|
By Joan Choo, Joseph J. Zhao, Mai Chan Lau, Alessandra Raimondi, Sruthi Ranganathan, Kexin Zhu, Chong Boon Teo, Khi Yung Fong, Jia-Ying Joey Lee, Lit-Hsin Loo, Paolo Manca, Federica Morano, Michele Prisciandaro, Giovanni Randon, Guido Leoni, Elisa Scarselli, Sara Lonardi, Chiara Cremolini, Federica Marmorino, Felicia Wee, Craig Joseph, Akhila Balachander, You Yi Hwang, Laurent Renia, David Tan, Joe Yeong, Raghav Sundar, Filippo Pietrantonio, Willa Wen-You Yim, Hui Xian Chin, Camilla Damonte, Elisa Micarelli, Zhen Wei Neo, Diana GS Lim, Subhra Kumar Biswas
| Nature Verified
Abstract Microsatellite-stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI). The MAYA trial used temozolomide (TMZ) in MGMT-silenced MSS mCRC, hypothesizing that TMZ-induced hypermutation could sensitize tumors to ICI; the primary endpoint was met, showing durable responses with TMZ plus ipilimumab and nivolumab.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified